SQZ Biotechnologies
Watertown, US · Founded 2013 · Delaware corporation · 1 known investors
Biotech
Founders & leadership
SQZ Biotechnologies was founded in 2013 by Robert S. Langer, Sc.D. and Armon Sharei, Ph.D..
RS
Robert S. Langer, Sc.D.Co-founder
AS
Armon Sharei, Ph.D.Co-founder
AW
Amy W. SchulmanExecutive
KE
Kris ElverumExecutive
HB
Howard BernsteinExecutive
KF
Klavs F. Jensen, Ph.D.Named on SEC filing
RL
Robert LangerNamed on SEC filing
KJ
Klavs JensenNamed on SEC filing
AL
Agustin Lopez-MarquezNamed on SEC filing
AS
Armon ShareiNamed on SEC filing
Board
JF
Jonathan FlemingBoard director
EM
Eric MoessingerBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$166.7M disclosed across 5 rounds · 2014–2019
▶$66.3MraisedJun 2020 · 27 investors · BiotechnologyRule 506(b)
▶$66.3MraisedJun 2020 · 27 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Howard Bernstein, M.D., Ph.D.Executive Officer
- Oliver Rosen, M.D.Executive Officer
- David FirstExecutive Officer
- Armon Sharei, Ph.D.Executive Officer, Director
- Eric MoessingerDirector
- Alexandra BalcomExecutive Officer
- Teri LoxamExecutive Officer
- Pushkal GargDirector
- Marc EliaDirector
- Zafrira AvnurDirector
- Lawrence KnopfExecutive Officer
- Klavs F. Jensen, Ph.D.Director
- Amy W. SchulmanDirector
- Jonathan FlemingDirector
- Offering amount
- $70.2M
- Amount sold
- $66.3M
- First sale
- Dec 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$71.3MraisedNov 2019 · 48 investors · BiotechnologyRule 506(b)
▶$71.3MraisedNov 2019 · 48 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jonathan FlemingDirector
- Armon Sharei, Ph.D.Executive Officer, Director
- Robert Langer, Sc.D.Director
- Klavs F. Jensen, Ph.D.Director
- Amy W. SchulmanDirector
- Pushkal GargDirector
- Eric MoessingerDirector
- Garry A. NicholsonDirector
- Marc EliaDirector
- Zafrira AvnurDirector
- Alex BalcomExecutive Officer
- Amount sold
- $71.3M
- First sale
- May 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$24.1MraisedDec 2016 · 34 investors · BiotechnologyRule 506(b)
▶$24.1MraisedDec 2016 · 34 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Amy W. SchulmanExecutive Officer, Director
- Mark Murcko, Ph.D.Director
- Kris ElverumExecutive Officer
- Garry A. NicholsonDirector
- Howard BernsteinExecutive Officer
- Robert S. Langer, Sc.D.Director
- Armon Sharei, Ph.D.Executive Officer, Director
- Jonathan FlemingDirector
- Eric MoessingerDirector
- Klavs F. Jensen, Ph.D.Director
- Offering amount
- $24.1M
- Amount sold
- $24.1M
- First sale
- Sep 2016
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
▶$5.1MraisedJul 2015 · 24 investors · BiotechnologyRule 506(b)
▶$5.1MraisedJul 2015 · 24 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jonathan FlemingDirector
- Klavs F. Jensen, Ph.D.Director
- Armon Sharei, Ph.D.Executive Officer, Director
- Robert Langer, Ph.D.Director
- Amy W. SchulmanDirector
- Offering amount
- $5.1M
- Amount sold
- $5.1M
- First sale
- Jun 2015
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
▶$15KraisedApr 2014 · 1 investors · BiotechnologyRule 506(b)
▶$15KraisedApr 2014 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Robert LangerDirector
- Klavs JensenExecutive Officer, Director
- Agustin Lopez-MarquezExecutive Officer
- Armon ShareiExecutive Officer, Director
- Offering amount
- $1M
- Amount sold
- $15K
- First sale
- Mar 2014
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 9 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2022 | $1M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $253.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $250K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2017 | $1.7M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2016 | $1.5M |
| National Science Foundation | Phase II | 2016 | $750K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2015 | $493.3K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2015 | $223.7K |
| National Science Foundation | Phase I | 2015 | $150K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- Who founded SQZ Biotechnologies?
- SQZ Biotechnologies was founded by Robert S. Langer, Sc.D., Armon Sharei, Ph.D. in 2013.
- Who are SQZ Biotechnologies's investors?
- SQZ Biotechnologies's investors include Veltro Argento.
- How much funding has SQZ Biotechnologies raised?
- SQZ Biotechnologies has disclosed $166.7M raised across 5 rounds.
- Where is SQZ Biotechnologies headquartered?
- SQZ Biotechnologies is headquartered in Watertown, US.